Softwr

Healthcare · head to head

NextGen Healthcare vs Paige

NextGen Healthcare logo

NextGen Healthcare

Healthcare

Integrated EHR and practice management solutions

From
$150/month
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: NextGen Healthcare no pricing published on website; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: NextGen Healthcare covers Electronic Health Records, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which NextGen Healthcare and Paige actually diverge.

Attributes where NextGen Healthcare and Paige differ
AttributeNextGen HealthcarePaige
Starting price$150/monthOn request
Pricing modelsubscriptionquote
PlatformsWeb, iOS, AndroidWeb, Cloud, On-premise
Founded1997Unknown

Identical on both: free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in NextGen Healthcare

  • Electronic Health Records
  • Practice Management
  • Revenue Cycle Management
  • Telehealth
  • Analytics
  • Labs
  • Pharmacies
  • Clearinghouses

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

NextGen Healthcare

  • Cloud-based EHR and practice management for ambulatory and specialty practicesnot Paige
  • AI-assisted clinical documentation to reduce after-hours charting timenot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot NextGen Healthcare
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot NextGen Healthcare
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot NextGen Healthcare
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot NextGen Healthcare

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

NextGen Healthcare

  • No pricing published on website

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

NextGen Healthcare

$150/month

No published plan breakdown. See the NextGen Healthcare review.

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose NextGen Healthcare if

  • You need electronic health records.
  • You work on Web, iOS, Android.
  • You also want practice management.
NextGen Healthcare review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is NextGen Healthcare or Paige better?
Neither clearly leads. NextGen Healthcare starts at $150/month and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, NextGen Healthcare or Paige?
NextGen Healthcare starts at $150/month and Paige at On request.
Does NextGen Healthcare or Paige run on more platforms?
NextGen Healthcare runs on Web, iOS, Android. Paige runs on Web, Cloud, On-premise.
What is NextGen Healthcare best used for?
NextGen Healthcare is most often used for cloud-based ehr and practice management for ambulatory and specialty practices, ai-assisted clinical documentation to reduce after-hours charting time. Of those, cloud-based ehr and practice management for ambulatory and specialty practices and ai-assisted clinical documentation to reduce after-hours charting time are not what Paige is typically brought in for.
What can NextGen Healthcare do that Paige cannot?
NextGen Healthcare covers Electronic Health Records, Practice Management, Revenue Cycle Management, Telehealth. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

NextGen Healthcare: How much does NextGen Healthcare cost?

NextGen Healthcare does not publish pricing on its website. The company directs customers to schedule a meeting, request a demo, or chat with sales to receive custom pricing.

Source
Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on NextGen Healthcare

More on Paige

Keep looking

Other head to heads